Independent Validation of a Prognostic Genomic Signature (ColoPrint) for Patients With Stage II Colon Cancer

Publication Name: Annals of Surgery

Author(s): Matthias Maak, MD, Iris Simon, PhD, Ulrich Nitsche, MD, Paul Roepman, PhD, Mireille Snel, MSc Annuska M. Glas, PhD

  Objectives: The aim of this study was to independently validate a genomic signature developed both to assess recurrence risk in stage II patients and to assist in treatment decisions.   Background: Adjuvant therapy is recommended for high-risk patients with … Continued

Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients

Publication Name: ASCO GI 2011

Author(s): R. Rosenberg, M. Maak, U. Nitsche, T. Schuster, B. Kuenzli, I. Simon, R. Bender, K. P. Janssen and H. Friess

Background: Adjuvant therapy is not routinely recommended for stage II CC patients but may be considered for high-risk patients. In this study we aim to independently validate a genomic profile that was developed to identify high-risk patients and can assist in … Continued

Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer

Publication Name: Journal of Clinical Oncology

Author(s): Ramon Salazar, Paul Roepman, Gabriel Capella, Victor Moreno, Iris Simon, Christa Dreezen, Adriana Lopez-Doriga, Cristina Santos, Corrie Marijnen, Johan Westerga, Sjoerd Bruin, David Kerr, Peter Kuppen, Cornelis van de Velde, Hans Morreau, Loes Van Velthuy

Purpose: This study aims to develop a robust gene expression classifier that can predict disease relapse in patients with early-stage colorectal cancer (CRC). Patients and Methods Fresh frozen tumor tissue from 188 patients with stage I to IV CRC undergoing … Continued